The new Lipid Innovation Center will manufacture pharmaceutical lipids for RNA medicines and other advanced therapies, with full production capacity expected by mid-2027.
The expanded authorization allows the German CDMO to manufacture sterile viral drug substances and investigational medicinal products, including advanced therapies.
The €5 million project adds fermentation capabilities and downstream processing equipment, increasing production capacity at the León site to 58,000 liters.
The certifications cover cell-based product development and medical device contract manufacturing, supporting the CDMO’s efforts to attract new customers.
The CDMO’s Suzhou facility will integrate electron diffraction into solid-form screening, with expedited crystal structure analysis available within 48 hours.
